| Date | Title | Description | Source |
| 19.04.2024 | Addex to Present at the Swiss Biotech Day 2024 | Geneva, Switzerland, April 19, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage ph... | einpresswi... |
| 18.04.2024 | Addex Therapeutics Reports Full Year 2023 Financial Results ... | Top-line data from ADX71149 Phase 2 epilepsy study expected by mid-May 2024 Launched Neurosterix wit... | einpresswi... |
| 11.04.2024 | Addex Therapeutics to Release Full-Year 2023 Financial Resul... | Geneva, Switzerland, April 11, 2024 – Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage ph... | einpresswi... |
| 03.04.2024 | Addex spin-off launched with USD63 million investment |
Addex Therapeutics is a clinical-stage biopharmaceutical company focused on developing a portfolio ... | startuptic... |
| 14.03.2024 | Addex to Present at the Bio-Europe Spring 2024 Conference | - | globenewsw... |
| 14.03.2024 | Addex to Present at the Bio-Europe Spring 2024 Conference | Geneva, Switzerland, March 14, 2024 – Addex Therapeutics (SIX: ADXN), a clinical-stage pharmaceutica... | einpresswi... |
| 05.01.2024 | Addex to Present at Biotech Showcase™ 2024 | CEO to provide update on allosteric modulator pipeline clinical and preclinical development
Geneva, ... | einpresswi... |
| 23.11.2023 | Addex Therapeutics to Release Third Quarter 2023 Financial R... | Geneva, Switzerland, November 23, 2023 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage... | einpresswi... |
| 15.08.2023 | Spexis and Addex attract new funds | | startuptic... |
| 05.04.2023 | Addex Completes $5.0 Million Equity Financing | - | globenewsw... |
| 05.04.2023 | Addex Completes $5.0 Million Equity Financing | Proceeds to advance allosteric modulator therapeutic pipeline
Ad Hoc Announcement Pursuant to Art. 5... | einpresswi... |
| 03.04.2023 | Addex Raises $5.0 Million in Equity Financing | - | globenewsw... |
| 03.04.2023 | Addex Raises $5.0 Million in Equity Financing | /EIN News/ -- Ad Hoc Announcement Pursuant to Art. 53 LR
Geneva, Switzerland, April 3, 2023 - Addex ... | einpresswi... |
| 14.03.2023 | The delisting dilemma: Why do so many biotechs face being ki... | The latest fear stalking biotech boardrooms isn’t a trial fail or an underwhelming funding haul, it’... | fiercebiot... |
| 20.09.2022 | Addex to Present at the Sachs Associates 22nd Annual Biotech... | Geneva, Switzerland, September 20, 2022 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stag... | globenewsw... |
| 26.07.2022 | Addex Completes $4.2 Million Equity Financing | Ad Hoc Announcement Pursuant to Art. 53 LR
Geneva, Switzerland, July 26, 2022 – Addex Therapeutics L... | globenewsw... |
| 22.07.2022 | Addex raised $4.2 million in equity funding | | startuptic... |
| 22.07.2022 | Addex Raises $4.2 million in Equity Financing | Ad Hoc Announcement Pursuant to Art. 53 LR
Geneva, Switzerland, July 22, 2022 – Addex Therapeutics L... | globenewsw... |
| 21.07.2022 | Addex Completes Reduction in Nominal Value of Shares | Ad Hoc Announcement Pursuant to Art. 53 LR
Geneva, Switzerland, July 21, 2022 - Addex Therapeutics L... | globenewsw... |
| 21.07.2022 | Addex Provides Corporate Update and Financial Guidance | Ad Hoc Announcement Pursuant to Art. 53 LR
Geneva, Switzerland, July 21, 2022 - Addex Therapeutics L... | globenewsw... |
| 17.06.2022 | Addex Terminates Dipraglurant Phase 2b/3 Study in Patients w... | COVID-19 related challenges negatively impacted patient recruitment
Ad Hoc Announcement Pursuant to ... | globenewsw... |
| 27.05.2022 | Addex Provides Update on Dipraglurant Blepharospasm Phase 2 ... | Ad Hoc Announcement Pursuant to Art. 53 LR
Geneva, Switzerland, May 27, 2022 - Addex Therapeutics Lt... | globenewsw... |
| 19.05.2022 | Addex Announces Participation in the H.C. Wainwright Global ... | Geneva, Switzerland, May 19, 2022 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-sta... | globenewsw... |
| 13.05.2022 | Addex Announces Participation in the 22nd Bio€quity Europe C... | Geneva, Switzerland, May 13, 2022 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-sta... | globenewsw... |
| 10.05.2022 | Addex Shareholders Approve All Resolutions at Annual General... | Ad Hoc Announcement Pursuant to Art. 53 LR
Geneva, Switzerland, May 10, 2022 – Addex Therapeutics (S... | globenewsw... |
| 05.05.2022 | Addex Reports Q1 2022 Financial Results | CHF14.9M ($16.1M) of cash and cash equivalents at March 31, 2022
Dipraglurant Phase 2 blepharospasm ... | globenewsw... |
| 28.04.2022 | Addex to Present at the Swiss Biotech Day 2022 | Geneva, Switzerland, April 28, 2022 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-s... | globenewsw... |
| 25.04.2022 | Addex to Present at the B. Riley Securities Neuro & Opht... | Geneva, Switzerland, April 25, 2022 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-s... | globenewsw... |
| 13.04.2022 | Addex Therapeutics Completes Patient Enrollment for Dipraglu... | Top-line Data Scheduled to Report in Q2 2022
Ad Hoc Announcement Pursuant to Art. 53 LR
Geneva, Swit... | globenewsw... |
| 06.04.2022 | Addex Expands Pipeline with Selective M4 Positive Allosteric... | New Series of Potent and Selective Compounds Identified Using Proprietary Allosteric Modulator Scree... | globenewsw... |
| 31.03.2022 | Addex Convenes Annual General Meeting 2022 | Ad Hoc Announcement Pursuant to Art. 53 LR
Geneva, Switzerland, March 31, 2022 - Addex Therapeutics ... | globenewsw... |
| 24.03.2022 | Addex to Present at the Bio-Europe Spring 2022 and Maxim Gro... | Geneva, Switzerland, March 24, 2022 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-st... | globenewsw... |
| 10.03.2022 | Addex Reports Full Year 2021 Financial Results and Provides ... | CHF20.5M ($22.5M) of cash and cash equivalents at December 31, 2021
Dipraglurant Phase 2 blepharospa... | globenewsw... |
| 07.03.2022 | Addex Therapeutics to Release Full-Year 2021 Financial Resul... | Geneva, Switzerland, March 7, 2022 – Addex Therapeutics (SIX: ADXN, Nasdaq: ADXN), a clinical-stage ... | globenewsw... |
| 03.02.2022 | Addex Increases Issued Share Capital to Create Treasury Shar... | Ad Hoc Announcement Pursuant to Art. 53 LR
Geneva, Switzerland, February 3, 2022 - Addex Therapeutic... | globenewsw... |
| 11.01.2022 | Addex to Present at the Swiss Equities Baader Virtual Confer... | Geneva, Switzerland, January 11, 2022 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-... | globenewsw... |
| 06.01.2022 | Addex to Present at the H.C. Wainwright BIOCONNECT Virtual C... | Geneva, Switzerland, January 6 2022 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-st... | globenewsw... |
| 20.12.2021 | Addex Therapeutics : Raises $10.0 Million in Equity Financin... | Addex Raises $10.0 Million in Equity Financing
Ad Hoc Announcement Pursuant to Art. 53 LR
Geneva, Sw... | marketscre... |
| 17.12.2021 | Addex Raises $10.0 Million in Equity Financing | (MORE TO FOLLOW) Dow Jones Newswires
December 17, 2021 01:00 ET (06:00 GMT) | marketscre... |
| 17.12.2021 | Addex Raises $10.0 Million in Equity Financing | Ad Hoc Announcement Pursuant to Art. 53 LR
Geneva, Switzerland, December 17, 2021 – Addex Therapeuti... | globenewsw... |
| 15.12.2021 | Addex Provides Year End Pipeline Development Update | Ad Hoc Announcement Pursuant to Art. 53 LR
Geneva, Switzerland, 15 December 2021 - Addex Therapeutic... | globenewsw... |
| 18.11.2021 | Addex to Present at the Virtual German Equity Forum | Geneva, Switzerland, November 18, 2021 - Addex Therapeutics (SIX: ADXN, Nasdaq: ADXN), a clinical-st... | globenewsw... |
| 15.11.2021 | Addex Strategic Partner Successfully Completes Phase 1 in Ja... | Setting Up Global Expansion of Phase 2 Clinical Evaluation in Epilepsy Patients
Ad Hoc Announcement ... | globenewsw... |
| 15.11.2021 | Addex to Present at the H.C. Wainwright 7th Annual Israel Vi... | Geneva, Switzerland, November 15, 2021 - Addex Therapeutics (SIX: ADXN, Nasdaq: ADXN), a clinical-st... | globenewsw... |
| 04.11.2021 | Addex Reports Q3 2021 Financial Results and Provides Corpora... | CHF15.5M ($16.6M) of cash and cash equivalents at September 30, 2021Cash used in Q3 2021 of CHF2.6MD... | globenewsw... |
| 01.11.2021 | Addex Therapeutics to Release Q3 2021 Financial Results and ... | Geneva, Switzerland, November 1, 2021 – Addex Therapeutics (SIX: ADXN, Nasdaq: ADXN), a clinical-sta... | globenewsw... |
| 06.10.2021 | Addex to Present at the Investors’ Day hosted by Voxia Commu... | Geneva, Switzerland, October 6, 2021 - Addex Therapeutics (SIX: ADXN, Nasdaq: ADXN), a clinical-stag... | globenewsw... |
| 29.06.2021 | Addex Therapeutics Initiates Pivotal Phase 2b/3 Study with D... | Geneva, Switzerland, June 29, 2021 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-st... | marketscre... |
| 09.03.2021 | Addex Therapeutics to Release Full-Year 2020 Financial Resul... | Geneva, Switzerland, March 9, 2021 – Addex Therapeutics (SIX:ADXN), a clinical-stage pharmaceutical ... | globenewsw... |
| 16.02.2021 | Addex GABAB Positive Allosteric Modulator Demonstrates Promi... | Review from Linköping University Published in Alcohol and Alcoholism Journal
Geneva, Switzerland, Fe... | globenewsw... |
| 03.11.2020 | Addex Therapeutics : Quarter 3 Report | Allosteric Modulators for Human Health
Quarter 3 2020
Interim Report
Quarter 3 Report│ Interim Conde... | marketscre... |
| 03.11.2020 | ADDEX THERAPEUTICS LTD
Addex Therapeutics : Quarter 3 Repor... | Allosteric Modulators for Human Health
Quarter 3 2020
Interim Report
Quarter 3 Report│ Interim Conde... | marketscre... |
| 20.09.2018 | Addex Receives £1.2 million Funding from the Wellcome Trust | | startuptic... |
| 02.07.2018 | Appello Pharmaceuticals nets $10.5 million in Series A fundi... | The company’s rationale for the drugs is that the current standard of care, dopamine replacement the... | medcitynew... |
| 05.03.2018 | Addex Secures Investor Commitment for CHF40 million Capital ... | | startuptic... |
| 03.01.2018 | Two biotech startups receive milestone payments | | startuptic... |
| 18.06.2012 | Addex to Present Phase 2a Dipraglurant Data at Movement Diso... | Geneva, Switzerland, 18 June 2012 – Addex Therapeutics (SIX:ADXN), a leading company pioneering allo... | tvm-lifesc... |
| 16.04.2012 | Addex Reports Positive Preclinical Data for GABA-BR PAM Oral... | Geneva, Switzerland, 16 April 2012 – Addex Therapeutics (SIX:ADXN), a leading organization pioneerin... | tvm-lifesc... |
| - | Appello Pharmaceuticals nets $10.5 million in Series A fundi... | A firm developing a drug class licensed from Vanderbilt University for Parkinson’s disease has secur... | medcitynew... |
